Morgan E Grams1, Casey M Rebholz2, Blaithin McMahon3, Seamus Whelton3, Shoshana H Ballew2, Elizabeth Selvin2, Lisa Wruck4, Josef Coresh5. 1. Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD. Electronic address: mgrams2@jhmi.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD. 4. Department of Biostatistics, University of North Carolina, Chapel Hill, NC. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD.
Abstract
BACKGROUND: In epidemiologic research, incident chronic kidney disease (CKD) commonly is determined by laboratory tests performed at planned study visits. Given the morbidity and mortality associated with CKD, persons with incident disease may be less likely to attend scheduled visits, affecting observed associations. The objective of this study was to quantify loss to follow-up by CKD status and determine whether supplementation with diagnostic code data improves capture of incident CKD. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 11,560 participants in the Atherosclerosis Risk in Communities (ARIC) Study underwent continuous surveillance for hospitalizations and death from baseline visit (1996-1999) to follow-up visit (2011-2013). A subset of hospitalizations in Washington County, MD, was used in diagnostic code validation (n=2,540). PREDICTOR: Baseline demographics and comorbid conditions. OUTCOMES: Incident CKD stage 3 ascertained by follow-up visit (visit-based definition) or hospitalization surveillance (hospitalization-based definition). MEASUREMENTS: Visit-based definition: ≥25% decline from baseline estimated glomerular filtration rate to <60 mL/min/1.73 m2 at follow-up visit; hospitalization-based definition: hospitalization CKD diagnostic code. RESULTS:Of 11,560 participants, 5,951 attended the follow-up visit and 9,264 were hospitalized. Never-hospitalized participants were younger, more often female, and had fewer comorbid conditions; 73.5% attended the follow-up visit. Incident CKD stage 3 occurred in 1,172 participants by the visit-based definition (251 were never hospitalized) and 1,078 participants by the hospitalization-based definition (237 attended the follow-up study visit). Sensitivity of the hospitalization-based CKD definition was 35.5% (95% CI, 31.6%-39.7%); specificity was 95.7% (95% CI, 94.2%-96.8%). Sensitivity was higher with later time period, older participant age, and baseline prevalent diabetes and CKD. LIMITATIONS: A subset of hospitalizations was used for validation; 15-year gap between study visits. CONCLUSIONS: The sensitivity of diagnostic code-identified CKD is low and varies by certain factors; however, supplementing a visit-based definition with hospitalization information can increase disease identification during periods of follow-up without study visits.
RCT Entities:
BACKGROUND: In epidemiologic research, incident chronic kidney disease (CKD) commonly is determined by laboratory tests performed at planned study visits. Given the morbidity and mortality associated with CKD, persons with incident disease may be less likely to attend scheduled visits, affecting observed associations. The objective of this study was to quantify loss to follow-up by CKD status and determine whether supplementation with diagnostic code data improves capture of incident CKD. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 11,560 participants in the Atherosclerosis Risk in Communities (ARIC) Study underwent continuous surveillance for hospitalizations and death from baseline visit (1996-1999) to follow-up visit (2011-2013). A subset of hospitalizations in Washington County, MD, was used in diagnostic code validation (n=2,540). PREDICTOR: Baseline demographics and comorbid conditions. OUTCOMES: Incident CKD stage 3 ascertained by follow-up visit (visit-based definition) or hospitalization surveillance (hospitalization-based definition). MEASUREMENTS: Visit-based definition: ≥25% decline from baseline estimated glomerular filtration rate to <60 mL/min/1.73 m2 at follow-up visit; hospitalization-based definition: hospitalization CKD diagnostic code. RESULTS: Of 11,560 participants, 5,951 attended the follow-up visit and 9,264 were hospitalized. Never-hospitalized participants were younger, more often female, and had fewer comorbid conditions; 73.5% attended the follow-up visit. Incident CKD stage 3 occurred in 1,172 participants by the visit-based definition (251 were never hospitalized) and 1,078 participants by the hospitalization-based definition (237 attended the follow-up study visit). Sensitivity of the hospitalization-based CKD definition was 35.5% (95% CI, 31.6%-39.7%); specificity was 95.7% (95% CI, 94.2%-96.8%). Sensitivity was higher with later time period, older participant age, and baseline prevalent diabetes and CKD. LIMITATIONS: A subset of hospitalizations was used for validation; 15-year gap between study visits. CONCLUSIONS: The sensitivity of diagnostic code-identified CKD is low and varies by certain factors; however, supplementing a visit-based definition with hospitalization information can increase disease identification during periods of follow-up without study visits.
Authors: Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Morgan E Grams; Sushrut S Waikar; Blaithin MacMahon; Seamus Whelton; Shoshana H Ballew; Josef Coresh Journal: Clin J Am Soc Nephrol Date: 2014-01-23 Impact factor: 8.237
Authors: Sushrut S Waikar; Ron Wald; Glenn M Chertow; Gary C Curhan; Wolfgang C Winkelmayer; Orfeas Liangos; Marie-Anne Sosa; Bertrand L Jaber Journal: J Am Soc Nephrol Date: 2006-04-26 Impact factor: 10.121
Authors: Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Abhijit V Kshirsagar; Heejung Bang; Andrew S Bomback; Suma Vupputuri; David A Shoham; Lisa M Kern; Philip J Klemmer; Madhu Mazumdar; Phyllis A August Journal: Arch Intern Med Date: 2008-12-08
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Carmen A Peralta; Ronit Katz; Mark J Sarnak; Joachim Ix; Linda F Fried; Ian De Boer; Walter Palmas; David Siscovick; Andrew S Levey; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2010-12-16 Impact factor: 14.978
Authors: Kelsie M Full; Chandra L Jackson; Casey M Rebholz; Kunihiro Matsushita; Pamela L Lutsey Journal: J Am Soc Nephrol Date: 2020-06-26 Impact factor: 10.121
Authors: Bethany Warren; Alexandra K Lee; Christie M Ballantyne; Ron C Hoogeveen; James S Pankow; Morgan E Grams; Anna Köttgen; Elizabeth Selvin Journal: J Appl Lab Med Date: 2020-11-01
Authors: Rasheeda K Hall; Richard Sloane; Carl Pieper; Courtney Van Houtven; Joanne LaFleur; Robert Adler; Cathleen Colón-Emeric Journal: J Am Geriatr Soc Date: 2018-01-10 Impact factor: 5.562
Authors: Casey M Rebholz; Morgan E Grams; Josef Coresh; Elizabeth Selvin; Lesley A Inker; Andrew S Levey; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Harold I Feldman; Chi-Yuan Hsu; Pamela L Lutsey Journal: J Am Soc Nephrol Date: 2014-07-24 Impact factor: 10.121
Authors: C M Parrinello; K Matsushita; M Woodward; L E Wagenknecht; J Coresh; E Selvin Journal: Diabetes Obes Metab Date: 2016-06-14 Impact factor: 6.577
Authors: Benjamin Lazarus; Yuan Chen; Francis P Wilson; Yingying Sang; Alex R Chang; Josef Coresh; Morgan E Grams Journal: JAMA Intern Med Date: 2016-02 Impact factor: 21.873
Authors: Yan Chen; Alex R Chang; Mara A McAdams DeMarco; Lesley A Inker; Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh; Morgan E Grams Journal: Mayo Clin Proc Date: 2016-08-04 Impact factor: 7.616
Authors: Bernhard Haring; Elizabeth Selvin; Menglu Liang; Josef Coresh; Morgan E Grams; Natalia Petruski-Ivleva; Lyn M Steffen; Casey M Rebholz Journal: J Ren Nutr Date: 2017-01-05 Impact factor: 3.655
Authors: Adrienne Tin; Robert Scharpf; Michelle M Estrella; Bing Yu; Megan L Grove; Patricia P Chang; Kunihiro Matsushita; Anna Köttgen; Dan E Arking; Eric Boerwinkle; Thu H Le; Josef Coresh; Morgan E Grams Journal: J Am Soc Nephrol Date: 2017-07-18 Impact factor: 10.121
Authors: Casey M Rebholz; Elizabeth Selvin; Menglu Liang; Christie M Ballantyne; Ron C Hoogeveen; David Aguilar; John W McEvoy; Morgan E Grams; Josef Coresh Journal: Kidney Int Date: 2017-08-31 Impact factor: 10.612